Johnson & Johnson (J&J) Develops the Third COVID-19 Vaccine to be Considered by U.S. Regulatory Authorities
The J&J vaccine division, Janssen Pharmaceuticals, reports that their vaccine is 66% protective against moderate to severe COVID-19 infection in a multi-country study. It was 85% protective against severe forms of disease. This vaccine only requires one shot, uses a viral vector approach as opposed to messenger RNA (mRNA), and can be kept at regular refrigerator temperatures. J&J will apply for Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA) this week. The EUA may be granted in late February or early March 2021. For more on how the COVID-19 vaccines differ, reference this Stat story.
Impact on General Dentistry: The AGD advocates for COVID-19 vaccines being available for general dentists, their team members, and the public. Additionally, the AGD supports the administration of vaccinations by general dentists who have attained the training and education to do so. AGD information on COVID vaccines with resources located on the left side of the page is located here.
Impact on General Dentistry: The AGD advocates for COVID-19 vaccines being available for general dentists, their team members, and the public. Additionally, the AGD supports the administration of vaccinations by general dentists who have attained the training and education to do so. AGD information on COVID vaccines with resources located on the left side of the page is located here.